首页 | 本学科首页   官方微博 | 高级检索  
   检索      


Comparative Efficacy of Lamivudine and Emtricitabine: A Systematic Review and Meta-Analysis of Randomized Trials
Authors:Nathan Ford  Zara Shubber  Andrew Hill  Marco Vitoria  Meg Doherty  Edward J Mills  Andy Gray
Institution:1. Department of HIV/AIDS, World Health Organization, Geneva, Switzerland.; 2. Department of Infectious Disease Epidemiology, Faculty of Medicine, Imperial College, London, United Kingdom.; 3. Pharmacology Research Laboratories, University of Liverpool, Liverpool, United Kingdom.; 4. Faculty of Health Sciences, University of Ottawa, Ottawa, Canada.; 5. Division of Pharmacology, School of Health Sciences, University of KwaZulu-Natal, Durban, South Africa.; McGill University AIDS Centre, Canada,
Abstract:

Introduction

Lamivudine and emtricitabine are considered equivalent by several guidelines, but evidence of comparable efficacy is conflicting.

Methods

We searched two databases up to June 30 2013 to identify randomized and quasi-randomized trials in which lamivudine and emtricitabine were used as part of combination antiretroviral therapy for treatment-naïve or experienced HIV-positive adult patients. We only included trials where partner drugs in the regimen were identical or could be considered to be comparable. We allowed for comparisons between tenofovir and abacavir provided the study population did not begin treatment with a viral load >100,000 copies/ml.

Results

12 trials contributed 15 different randomized comparisons providing data on 2251 patients receiving lamivudine and 2662 patients receiving emtricitabine. Treatment success was not significantly different in any of the 12 trials. In the three trials that directly compared lamivudine and emtricitabine, the relative risk for achieving treatment success was non-significant (RR 1.03 95%CI 0.96-1.10). For all trials combined, the pooled relative risk for treatment success was not significantly different (RR 1.00, 95%CI 0.97–1.02). No heterogeneity was observed (I 2 = 0). Similarly, there was no difference in the pooled relative risk for treatment failure (RR 1.08, 95%CI 0.94–1.22, I 2 = 3.4%).

Conclusions

The findings of this systematic review suggest that lamivudine and emtricitabine are clinically equivalent.
Keywords:
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号